Human Pluripotent Stem Cell Differentiation into Pancreatic Endocrine Cells

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for differentiating human pluripotent stem cells into pancreatic endocrine cells are inefficient and do not fully replicate the developmental program of higher mammals, such as humans, necessitating the development of improved conditions for expanding stem cell lines that can differentiate into pancreatic endocrine cells.

Innovation Solution

A method involving culturing human definitive endoderm cells with fibroblast growth factor 2 (FGF-2), retinoic acid, and activin A, followed by further differentiation in media with retinoic acid or retinoic acid and FGF-2, to produce pancreatic endocrine cells expressing NKX2.2 and belonging to the β-cell lineage.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If human pluripotent stem cells are differentiated into pancreatic endocrine cells using conventional methods, then pancreatic endocrine cells are produced, but the differentiation efficiency is low and the developmental program does not fully replicate human development

Engineering Contradiction:
Improvedifferentiation efficiencyVSAvoiddevelopmental program fidelity
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The differentiation process is divided into distinct sequential stages: definitive endoderm formation, pancreatic endoderm specification, and pancreatic endocrine cell differentiation. Each stage uses specific growth factor combinations (Activin A for definitive endoderm, FGF2 and Retinoic Acid for pancreatic endoderm, followed by pancreatic endocrine differentiation) to guide cells through human-replicative developmental pathways, improving both efficiency and fidelity simultaneously

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention optimizes multiple culture parameters including growth factor concentrations, culture medium composition, and differentiation timing to enhance differentiation efficiency while maintaining faithful replication of human pancreatic developmental programs

Inventive Principle:
Principle #35Parameter changes

2Quantity of substance

If stem cell lines are expanded for clinical use, then sufficient cell numbers are obtained, but the ability to differentiate into pancreatic endocrine cells may be compromised

Engineering Contradiction:
Improvestem cell numberVSAvoiddifferentiation capacity
Core Design Contradiction:
Quantity of substanceVSAdaptability or versatility

Solution Approach 1:

The invention establishes and maintains pluripotent stem cell lines with optimized characteristics before differentiation is initiated. By pre-characterizing and selecting stem cell lines with high differentiation potential, the method ensures that expanded cell populations retain the capacity to differentiate into pancreatic endocrine cells, addressing both quantity and adaptability requirements

Inventive Principle:
Principle #10Preliminary action

Data Source

PatentEP3527658B1Differentiation of human embryonic stem cells
Publication Date: 2024.07.24 JANSSEN BIOTECH INC
  • EP3527658B1 patent drawingFigure 1a)~1b)
  • EP3527658B1 patent drawingFigure 2a)~2c)
  • EP3527658B1 patent drawingFigure 3A~3D

AI summary

The present invention provides methods to promote the differentiation of pluripotent stem cells. In particular, the present invention provides an improved method for the formation of pancreatic endoderm, pancreatic hormone expressing cells and pancreatic hormone secreting cells. The present invention also provides methods to promote the differentiation of pluripotent stem cells without the use of a feeder cell layer.